Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies
暂无分享,去创建一个
[1] Nancy Y. Villa,et al. Ex vivo virotherapy with myxoma virus does not impair hematopoietic stem and progenitor cells. , 2016, Cytotherapy.
[2] J. Goldberg,et al. CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[3] C. Lengerke,et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey , 2015, Leukemia.
[4] G. McFadden,et al. Prevention of EBV lymphoma development by oncolytic myxoma virus in a murine xenograft model of post-transplant lymphoproliferative disease. , 2015, Biochemical and biophysical research communications.
[5] Nancy Y. Villa,et al. Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells. , 2015, Blood.
[6] C. Bordignon,et al. Improving the safety of cell therapy with the TK-suicide gene , 2015, Front. Pharmacol..
[7] M. Hallek,et al. [Allogeneic haematopoietic stem cell transplantation - an overview]. , 2015, Klinische Monatsblatter fur Augenheilkunde.
[8] S. Mineishi,et al. State-of-the-art acute and chronic GVHD treatment , 2015, International Journal of Hematology.
[9] J. Ritz,et al. Aberrant B-cell homeostasis in chronic GVHD. , 2015, Blood.
[10] G. Rosner,et al. Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. , 2014, Blood.
[11] J. Jagdeo,et al. Treatment of chronic graft-versus-host disease with bortezomib. , 2014, Blood.
[12] M. Tanimoto,et al. Programmed Death-1 Pathway in Host Tissues Ameliorates Th17/Th1-Mediated Experimental Chronic Graft-versus-Host Disease , 2014, The Journal of Immunology.
[13] S. Choi,et al. Current and emerging strategies for the prevention of graft-versus-host disease , 2014, Nature Reviews Clinical Oncology.
[14] L. Gonçalves,et al. Randomized double-blind clinical trial comparing clobetasol and dexamethasone for the topical treatment of symptomatic oral chronic graft-versus-host disease. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[15] C. Cancrini,et al. HLA-haploidentical stem cell transplantation after removal of αβ+ T and B cells in children with nonmalignant disorders. , 2014, Blood.
[16] G. Hill,et al. The biology of graft-versus-host disease: experimental systems instructing clinical practice. , 2014, Blood.
[17] R. Skinner,et al. Recent advances in the management of graft-versus-host disease , 2014, Archives of Disease in Childhood.
[18] R. Krance,et al. Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. , 2014, Blood.
[19] C. Peschel,et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. , 2014, Blood.
[20] A. Mócsai,et al. Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage , 2014, Nature Medicine.
[21] W. Wiktor-Jedrzejczak,et al. Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practice , 2014, Bone Marrow Transplantation.
[22] F. Baron,et al. Thinking Out of the Box—New Approaches to Controlling GVHD , 2014, Current Hematologic Malignancy Reports.
[23] C. Ebens,et al. Notch signaling in hematopoietic cell transplantation and T cell alloimmunity. , 2013, Blood reviews.
[24] G. Freeman,et al. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. , 2013, Blood.
[25] A. Beg,et al. Pharmacologic inhibition of PKCα and PKCθ prevents GVHD while preserving GVL activity in mice. , 2013, Blood.
[26] M. Idzko,et al. The Nlrp3 inflammasome regulates acute graft-versus-host disease , 2013, The Journal of experimental medicine.
[27] G. McFadden,et al. Oncolytic myxoma virus: the path to clinic. , 2013, Vaccine.
[28] G. McFadden,et al. Myxoma Virus Protein M029 Is a Dual Function Immunomodulator that Inhibits PKR and Also Conscripts RHA/DHX9 to Promote Expanded Host Tropism and Viral Replication , 2013, PLoS pathogens.
[29] D. Roelen,et al. Proteasome Inhibition Profoundly Affects Activated Human B Cells , 2013, Transplantation.
[30] J. Apperley,et al. Treatment and management of graft-versus-host disease: improving response and survival , 2013, Therapeutic advances in hematology.
[31] J. Licht,et al. Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. , 2013, Immunity.
[32] G. McFadden,et al. Myxoma and Vaccinia Viruses Bind Differentially to Human Leukocytes , 2013, Journal of Virology.
[33] K. MacDonald,et al. Biology of graft-versus-host responses: recent insights. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[34] M. Pasquini,et al. 2013 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. , 2013, Clinical transplants.
[35] M. Tanimoto,et al. Chronic graft-versus-host disease: disease biology and novel therapeutic strategies. , 2013, Acta medica Okayama.
[36] G. McFadden,et al. Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[37] G. Núñez,et al. Orchestrating Inflammasomes , 2012, Science.
[38] J. O’Shea,et al. STAT3 transcription factor promotes instability of nTreg cells and limits generation of iTreg cells during acute murine graft-versus-host disease. , 2012, Immunity.
[39] G. McFadden,et al. Virotherapy Using Myxoma Virus Prevents Lethal Graft-versus-Host Disease following Xeno-Transplantation with Primary Human Hematopoietic Stem Cells , 2012, PloS one.
[40] J. Wingard,et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[41] Bruce R. Blazar,et al. Advances in graft-versus-host disease biology and therapy , 2012, Nature Reviews Immunology.
[42] E. Scott,et al. Acute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro. , 2012, Leukemia research.
[43] P. Kerr. Myxomatosis in Australia and Europe: a model for emerging infectious diseases. , 2012, Antiviral research.
[44] M. Tanimoto,et al. Synthetic retinoid Am80 ameliorates chronic graft-versus-host disease by down-regulating Th1 and Th17. , 2012, Blood.
[45] S. Kim,et al. B cell homeostasis and the development of chronic graft-versus-host disease: implications for B cell-depleting therapy , 2012, Leukemia & lymphoma.
[46] G. McFadden,et al. Oncolytic Virotherapy for Hematological Malignancies , 2011, Advances in virology.
[47] M. Caligiuri,et al. Regulation of acute graft-versus-host disease by microRNA-155. , 2010, Blood.
[48] S. Varambally,et al. Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells. , 2012, Blood.
[49] P. Chumakov,et al. Oncolytic poxviruses , 2012, Molecular Genetics, Microbiology and Virology.
[50] A. Sepulveda,et al. Absence of Stat1 in donor CD4⁺ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice. , 2011, The Journal of clinical investigation.
[51] M. Idzko,et al. Danger signals activating innate immunity in graft-versus-host disease , 2011, Journal of Molecular Medicine.
[52] C. Cutler,et al. Rituximab for prevention and treatment of graft-versus-host disease , 2011, International journal of hematology.
[53] Kailin Xu,et al. Control of mouse graft-versus-host disease following allogeneic bone marrow transplantation by blocking the CD28/B7 signaling pathway with lentiviral vector-mediated RNA interference. , 2011, Immunology letters.
[54] R. Storb,et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. , 2011, Blood.
[55] J. Kanda,et al. Alemtuzumab for the prevention and treatment of graft-versus-host disease , 2011, International journal of hematology.
[56] C. Perreault,et al. SMAD3 prevents graft-versus-host disease by restraining Th1 differentiation and granulocyte-mediated tissue damage. , 2011, Blood.
[57] Thomas B. Sundberg,et al. Manipulating the Bioenergetics of Alloreactive T Cells Causes Their Selective Apoptosis and Arrests Graft-Versus-Host Disease , 2011, Science Translational Medicine.
[58] S. Choi,et al. HDAC Inhibition and Graft Versus Host Disease , 2011, Molecular medicine.
[59] W. Pear,et al. Notch signaling is a critical regulator of allogeneic CD4+ T-cell responses mediating graft-versus-host disease. , 2009, Blood.
[60] J. Grandis,et al. Sequential activation of inflammatory signaling pathways during graft-versus-host disease (GVHD): early role for STAT1 and STAT3. , 2011, Cellular immunology.
[61] M. Martinka,et al. Cutaneous GVHD is associated with the expansion of tissue-localized Th1 and not Th17 cells. , 2010, Blood.
[62] E. Holler,et al. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[63] M. Idzko,et al. Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R , 2010, Nature Medicine.
[64] B. Kwon. Intervention with costimulatory pathways as a therapeutic approach for graft-versus-host disease , 2010, Experimental & Molecular Medicine.
[65] Kailin Xu,et al. Engineered regulatory T cells prevent graft-versus-host disease while sparing the graft-versus-leukemia effect after bone marrow transplantation. , 2010, Leukemia research.
[66] M. Robin,et al. Th17/Treg ratio in human graft-versus-host disease. , 2010, Blood.
[67] W. Shannon,et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. , 2010, Blood.
[68] G. McFadden,et al. The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status , 2010, Oncogene.
[69] Nancy Y. Villa,et al. Myxoma and vaccinia viruses exploit different mechanisms to enter and infect human cancer cells. , 2010, Virology.
[70] E. Robinet,et al. Genetically engineered T-cells expressing a ganciclovir-sensitive HSV-tk suicide gene for the prevention of GvHD. , 2010, Current opinion in investigational drugs.
[71] G. McFadden,et al. Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus. , 2010, Cytokine & growth factor reviews.
[72] C. Bordignon,et al. Clinical impact of suicide gene therapy in allogeneic hematopoietic stem cell transplantation. , 2010, Human gene therapy.
[73] Ryan M. O’Connell,et al. Physiological and pathological roles for microRNAs in the immune system , 2010, Nature Reviews Immunology.
[74] G. McFadden,et al. Pharmacological Manipulation of the Akt Signaling Pathway Regulates Myxoma Virus Replication and Tropism in Human Cancer Cells , 2010, Journal of Virology.
[75] M. Pasquini,et al. 2010 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. , 2010, Clinical transplants.
[76] D. Hanauer,et al. New perspectives on the biology of acute GVHD , 2010, Bone Marrow Transplantation.
[77] R. Storb,et al. The role of B cells in the pathogenesis of graft-versus-host disease. , 2009, Blood.
[78] M. Prlic,et al. PKCθ Is Required For Alloreactivity And GVHD But Not For Immune Responses Toward Leukemia And Infection In Mice , 2010 .
[79] E. Scott,et al. Myxoma Virus Targets Primary Human Leukemic Stem and Progenitor Cells While Sparing Normal Hematopoietic Stem and Progenitor Cells , 2009, Leukemia.
[80] G. McFadden,et al. Human cancer cells have specifically lost the ability to induce the synergistic state caused by tumor necrosis factor plus interferon-beta. , 2009, Cytokine.
[81] M. Hessner,et al. Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. , 2009, Blood.
[82] G. Baier,et al. PKC theta cooperates with PKC alpha in alloimmune responses of T cells in vivo. , 2009, Molecular immunology.
[83] X. Li,et al. Costimulatory pathways in transplantation: challenges and new developments , 2009, Immunological reviews.
[84] W. Swaim,et al. Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa. , 2009, Blood.
[85] Christopher G. King,et al. IL-17 contributes to CD4-mediated graft-versus-host disease. , 2009, Blood.
[86] B. Blazar,et al. Acute graft-versus-host disease: from the bench to the bedside. , 2005, Blood.
[87] Arnon Nagler,et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. , 2008, Blood.
[88] H. Baker,et al. The Addition of Tumor Necrosis Factor plus Beta Interferon Induces a Novel Synergistic Antiviral State against Poxviruses in Primary Human Fibroblasts , 2008, Journal of Virology.
[89] J. Antin,et al. Current and future approaches for control of graft-versus-host disease , 2008, Expert review of hematology.
[90] T. Yi,et al. Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease. , 2008, Blood.
[91] S. Amadori,et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. , 2008, Blood.
[92] G. Schwarzer,et al. Corticosteroids for preventing graft-versus-host disease after allogeneic myeloablative stem cell transplantation. , 2008, The Cochrane database of systematic reviews.
[93] Kerstin Amann,et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis , 2008, Nature Medicine.
[94] C. Dinarello,et al. Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. , 2008, The Journal of clinical investigation.
[95] P. Mclaughlin,et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. , 2008, Blood.
[96] G. Schwarzer,et al. Corticosteroids in the prevention of graft-vs-host disease after allogeneic myeloablative stem cell transplantation: a systematic review and meta-analysis , 2008, Leukemia.
[97] D. Jain,et al. Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease. , 2008, Blood.
[98] J. Serody,et al. The biology and therapeutic potential of natural regulatory T-cells in the bone marrow transplant setting , 2008, Leukemia & lymphoma.
[99] L. Naldini,et al. Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[100] R. Ortíz-López,et al. Oncolytic virotherapy. , 2008, Annals of hepatology.
[101] L. Kanz,et al. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update. , 2008, Blood cells, molecules & diseases.
[102] G. McFadden,et al. The role of cell signaling in poxvirus tropism: the case of the M-T5 host range protein of myxoma virus. , 2008, Biochimica et biophysica acta.
[103] F. Locatelli,et al. Searching for alternative hematopoietic stem cell donors for pediatric patients , 2008, Bone Marrow Transplantation.
[104] Stephanie J. Lee,et al. Recognizing and managing chronic graft-versus-host disease. , 2008, Hematology. American Society of Hematology. Education Program.
[105] R. Medzhitov. Recognition of microorganisms and activation of the immune response , 2007, Nature.
[106] D. Jacobsohn,et al. Acute graft-versus-host disease. , 1990, Cancer treatment and research.
[107] G. McFadden,et al. Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer , 2007, Expert opinion on biological therapy.
[108] D. Hockenbery,et al. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. , 2007, Blood.
[109] W. Shlomchik,et al. Graft-versus-host disease , 2007, Nature Reviews Immunology.
[110] M. Kubo,et al. Involvement of the Programmed Death-1/Programmed Death-1 Ligand Pathway in CD4+CD25+ Regulatory T-Cell Activity to Suppress Alloimmune Responses , 2007, Transplantation.
[111] X. Puente,et al. LPS Responsiveness and Neutrophil Chemotaxis In Vivo Require PMN MMP-8 Activity , 2007, PloS one.
[112] W. Murphy,et al. Immunobiology of allogeneic hematopoietic stem cell transplantation. , 2007, Annual review of immunology.
[113] J. Ferrara. Novel strategies for the treatment and diagnosis of graft-versus-host-disease. , 2007, Best practice & research. Clinical haematology.
[114] G. McFadden,et al. Myxoma virus in the European rabbit: interactions between the virus and its susceptible host. , 2007, Veterinary research.
[115] D. Harlan,et al. T cell–directed therapies: lessons learned and future prospects , 2007, Nature Immunology.
[116] J. Ritz,et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[117] Richard A Flavell,et al. Transforming growth factor-beta regulation of immune responses. , 2006, Annual review of immunology.
[118] J. Cheng,et al. Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[119] C. Bordignon,et al. Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. , 2005, Blood.
[120] N. Chao,et al. Prophylaxis and treatment of acute graft-versus-host disease. , 2006, Seminars in hematology.
[121] Catherine J. Wu,et al. Induction of tumor immunity following allogeneic stem cell transplantation. , 2006, Advances in immunology.
[122] H. Deeg,et al. The clinical spectrum of acute graft-versus-host disease. , 2006, Seminars in hematology.
[123] J. Ferrara,et al. Pathophysiology of graft-versus-host disease. , 2006, Seminars in hematology.
[124] H. Deeg,et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis , 2006, Leukemia.
[125] J. Sierra,et al. Donor age and degree of HLA matching have a major impact on the outcome of unrelated donor haematopoietic cell transplantation for chronic myeloid leukaemia , 2006, Bone Marrow Transplantation.
[126] Jiang Zhu,et al. Host-reactive CD8+ memory stem cells in graft-versus-host disease , 2005, Nature Medicine.
[127] T. Sayers,et al. Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. , 2005, Blood.
[128] R. Korngold,et al. A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses , 2005, Nature Medicine.
[129] M. V. D. van den Brink,et al. Absence of inducible costimulator on alloreactive T cells reduces graft versus host disease and induces Th2 deviation. , 2005, Blood.
[130] J. Wagner,et al. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II–III trial , 2005, The Lancet.
[131] H. Deeg,et al. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[132] A. Hinke,et al. Cyclosporine A and Mycophenolate Mofetil vs Cyclosporine A and Methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings , 2005, Bone Marrow Transplantation.
[133] J. Serody,et al. Leukocyte migration and graft-versus-host disease. , 2005, Blood.
[134] G. Yanik,et al. Acute graft versus host disease: pathophysiology, risk factors, and prevention strategies. , 2005, Clinical advances in hematology & oncology : H&O.
[135] A. García‐Díez,et al. Life-threatening graft-vs-host disease. , 2005, Clinics in dermatology.
[136] A. Rudensky,et al. Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM). , 2005, Blood.
[137] Jiang Zhu,et al. Alloreactive Memory T Cells Are Responsible for the Persistence of Graft-versus-Host Disease1 , 2005, The Journal of Immunology.
[138] A. Hanash,et al. Donor CD4+CD25+ T cells promote engraftment and tolerance following MHC-mismatched hematopoietic cell transplantation. , 2005, Blood.
[139] Todd E DeFor,et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. , 2005, Blood.
[140] P. Rao,et al. Differentiation and Expansion of T Cells with Regulatory Function from Human Peripheral Lymphocytes by Stimulation in the Presence of TGF-β , 2005, The Journal of Immunology.
[141] J. Serody,et al. L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. , 2004, Blood.
[142] D. Fisher,et al. Partial CD8+ T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease , 2004, Bone Marrow Transplantation.
[143] J. Wagner,et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. , 2004, The New England journal of medicine.
[144] M. Labopin,et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. , 2004, The New England journal of medicine.
[145] Harriet Noreen,et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. , 2004, Blood.
[146] T. Mak,et al. CD30/CD30 Ligand (CD153) Interaction Regulates CD4+ T Cell-Mediated Graft-versus-Host Disease1 , 2004, The Journal of Immunology.
[147] D. Jain,et al. Donor APCs are required for maximal GVHD but not for GVL , 2004, Nature Medicine.
[148] R. Storb,et al. Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review , 2004, Springer Seminars in Immunopathology.
[149] G. Hale,et al. Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here? , 2004, Transplantation proceedings.
[150] O. Joffre,et al. Induction of antigen-specific tolerance to bone marrow allografts with CD4+CD25+ T lymphocytes. , 2004, Blood.
[151] J. Serody,et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[152] Russell G. Jones,et al. PKCθ Signals Activation versus Tolerance In Vivo , 2004, The Journal of experimental medicine.
[153] N. Chao,et al. Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease. , 2004, Blood.
[154] J. Bolaños-Meade,et al. Acute graft-versus-host disease. , 2004, Clinical advances in hematology & oncology : H&O.
[155] J. Mary,et al. Prognostic value of apoptotic cells and infiltrating neutrophils in graft-versus-host disease of the gastrointestinal tract in humans: TNF and Fas expression. , 2004, Blood.
[156] C. Fathman,et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation , 2003, Nature Medicine.
[157] A. Panoskaltsis-Mortari,et al. Blockade of Programmed Death-1 Engagement Accelerates Graft-Versus-Host Disease Lethality by an IFN-γ-Dependent Mechanism1 , 2003, The Journal of Immunology.
[158] M. Shlomchik,et al. Memory CD4+ T cells do not induce graft-versus-host disease. , 2003, The Journal of clinical investigation.
[159] A. Sharpe,et al. Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients. , 2003, Blood.
[160] J. Ferrara,et al. Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects. , 2003, Blood.
[161] D. Bishop,et al. Contrasting Alloreactive CD4+ and CD8+ T Cells: There's More to It Than MHC Restriction , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[162] T. Nomura,et al. Control of Regulatory T Cell Development by the Transcription Factor Foxp3 , 2002 .
[163] Eun Young Choi,et al. Immunodominance of H60 is caused by an abnormally high precursor T cell pool directed against its unique minor histocompatibility antigen peptide. , 2002, Immunity.
[164] C. Fathman,et al. Donor-type CD4+CD25+ Regulatory T Cells Suppress Lethal Acute Graft-Versus-Host Disease after Allogeneic Bone Marrow Transplantation , 2002, The Journal of experimental medicine.
[165] John P Klein,et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. , 2002, Blood.
[166] F. Uckun,et al. Janus kinase 3 inhibitor WHI-P131/JANEX-1 prevents graft-versus-host disease but spares the graft-versus-leukemia function of the bone marrow allografts in a murine bone marrow transplantation model. , 2002, Blood.
[167] M. Sykes,et al. Donor-derived interferon gamma separates graft-versus-leukemia effects and graft-versus-host disease induced by donor CD8 T cells. , 2002, Blood.
[168] B. Blazar,et al. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. , 2002, Blood.
[169] S. Burakoff,et al. Cytolytic pathways in haematopoietic stem-cell transplantation , 2002, Nature Reviews Immunology.
[170] Lieping Chen,et al. Blockade of LIGHT/LTβ and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease , 2002 .
[171] F. Uckun,et al. Treatment of Post-Bone Marrow Transplant Acute Graft-Versus-Host Disease with a Rationally Designed JAK3 Inhibitor , 2002, Leukemia & lymphoma.
[172] Lieping Chen,et al. Blockade of LIGHT/LTbeta and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. , 2002, The Journal of clinical investigation.
[173] P. Mclaughlin,et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. , 2001, Blood.
[174] G. Freeman,et al. CD4+CD25high Regulatory Cells in Human Peripheral Blood1 , 2001, The Journal of Immunology.
[175] W. Harmsen,et al. Prophylaxis of graft-versus-host disease with cyclosporine–prednisone is associated with increased risk of chronic graft-versus-host disease , 2001, Bone Marrow Transplantation.
[176] J. Peschon,et al. Ligation of 4-1BB (CDw137) Regulates Graft-Versus-Host Disease, Graft-Versus-Leukemia, and Graft Rejection in Allogeneic Bone Marrow Transplant Recipients1 , 2001, The Journal of Immunology.
[177] R. Bronson,et al. Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets. , 2000, The Journal of clinical investigation.
[178] C. Springer,et al. Prodrug-activating systems in suicide gene therapy. , 2000, The Journal of clinical investigation.
[179] G. Hill,et al. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. , 2000, Blood.
[180] F. Fenner,et al. Adventures with poxviruses of vertebrates. , 2000, FEMS microbiology reviews.
[181] N. Chao,et al. Pathophysiologic mechanisms of acute graft-vs.-host disease. , 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[182] R. Storb,et al. A phase I-II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from donor marrow for HLA-mismatched unrelated recipients. , 1999, Blood.
[183] M. Shlomchik,et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. , 1999, Science.
[184] L. Dinkelborg,et al. HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY A High-Affinity Human Antibody That Targets Tumoral Blood Vessels , 1999 .
[185] R. Flavell,et al. Cutting edge: sustained expansion of CD8+ T cells requires CD154 expression by Th cells in acute graft versus host disease. , 1999, Journal of immunology.
[186] D. Taub,et al. Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. , 1998, The Journal of clinical investigation.
[187] M. Martelli,et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. , 1998, The New England journal of medicine.
[188] C. Anasetti,et al. Role of CD28 in acute graft-versus-host disease. , 1998, Blood.
[189] Y. Hsu,et al. TWEAK, a New Secreted Ligand in the Tumor Necrosis Factor Family That Weakly Induces Apoptosis* , 1997, The Journal of Biological Chemistry.
[190] J. Crawford,et al. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. , 1997, Blood.
[191] Arul M. Chinnaiyan,et al. The Receptor for the Cytotoxic Ligand TRAIL , 1997, Science.
[192] R. Flavell,et al. Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. , 1997, Journal of immunology.
[193] R. Collins,et al. FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation. , 1996, Blood.
[194] J. Tschopp,et al. Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease , 1996, The Journal of experimental medicine.
[195] J. Ferrara,et al. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. , 1995, Blood.
[196] M. Martelli,et al. Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells. , 1995, Immunology today.
[197] C. June,et al. Acute graft-versus-host reaction can be aborted by blockade of costimulatory molecules. , 1995, Journal of immunology.
[198] M. Toda,et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. , 1995, Journal of immunology.
[199] N. Schmitz,et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor) , 1995, Blood.
[200] M. Eckhaus,et al. Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. , 1994, Blood.
[201] A. Aruffo,et al. Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft-vs-host disease. , 1994, The Journal of clinical investigation.
[202] H Hengartner,et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. , 1994, Science.
[203] P. Linsley,et al. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. , 1994, Blood.
[204] C. Bordignon,et al. Graft failures after T cell depleted marrow transplants for leukemia: clinical and in vitro characteristics. , 1987, Transplantation proceedings.
[205] H. Deeg,et al. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. , 1986, Blood.
[206] B. Dupont,et al. Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. , 1983, Blood.
[207] R. Good,et al. TRANSPLANTATION FOR ACUTE LEUKAEMIA WITH HLA-A AND B NONIDENTICAL PARENTAL MARROW CELLS FRACTIONATED WITH SOYBEAN AGGLUTININ AND SHEEP RED BLOOD CELLS , 1981, The Lancet.
[208] R. Good,et al. ALLOGENEIC BONE MARROW TRANSPLANTATION USING STEM CELLS FRACTIONATED BY LECTINS: VI, IN VITRO ANALYSIS OF HUMAN AND MONKEY BONE MARROW CELLS FRACTIONATED BY SHEEP RED BLOOD CELLS AND SOYBEAN AGGLUTININ , 1980, The Lancet.
[209] J. Sloane,et al. CYCLOSPORIN A TO PREVENT GRAFT-VERSUS-HOST DISEASE IN MAN AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION , 1980, The Lancet.
[210] R. Storb,et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. , 1979, The New England journal of medicine.
[211] J. Sprent,et al. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow , 1978, The Journal of experimental medicine.
[212] A. Meshorer,et al. Hemopoietic stem cell transplantation using mouse bone marrow and spleen cells fractionated by lectins. , 1978, Proceedings of the National Academy of Sciences of the United States of America.
[213] P. Neiman,et al. Allogeneic marrow grafting for treatment of aplastic anemia. , 1974, Blood.
[214] R. Gatti,et al. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. , 1968, Lancet.
[215] Billingham Re. The biology of graft-versus-host reactions. , 1966 .
[216] R. Billingham. The biology of graft-versus-host reactions. , 1966, Harvey lectures.
[217] J. Loutit,et al. “SECONDARY DISEASE” OF RADIATION CHIMERAS: A SYNDROME DUE TO LYMPHOID APLASIA , 1962, Annals of the New York Academy of Sciences.
[218] E. Shelton,et al. Modification of irradiation injury in mice and guinea pigs by bone marrow injections. , 1951, Journal of the National Cancer Institute.
[219] L. Jacobson,et al. The role of the spleen in radiation injury and recovery. , 1950, The Journal of laboratory and clinical medicine.